Canada · Delayed Price · Currency is CAD Medicenna Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
MDNA11 is showing strong response rates in solid tumors, with pivotal trial planning underway. MDNA113, a novel bispecific anti-PD-1, demonstrated superior safety and efficacy in preclinical models and is set for clinical entry by year-end. MDNA55 is advancing toward phase III with a partner.
Fiscal Year 2025
-
MDNA11 demonstrated strong efficacy and a favorable safety profile in refractory solid tumors, with durable responses and high disease control rates in post-checkpoint inhibitor settings. KOLs highlighted its best-in-class potential and recommended expanding key cohorts and combination studies.
-
The conference detailed progress on a pipeline of engineered cytokine immunotherapies, highlighting strong clinical data for MDNA11 in refractory cancers and a robust outlook for upcoming data readouts. Multiple programs target large markets, with significant value inflection expected in December.
-
MDNA11 demonstrates strong response rates in hard-to-treat cancers, with pivotal data expected by year-end. The pipeline includes next-generation bispecifics and a Phase 3-ready asset, supported by solid financials and ongoing partnership efforts.
-
Lead asset MDNA11 shows strong response rates and safety in advanced cancer trials, with key data and enrollment completion expected by year-end. The pipeline includes a novel bispecific superkine and a glioblastoma therapy that doubled survival, supported by a robust patent portfolio.
-
The conference highlighted promising clinical data for MDNA-11, with response rates of 30%-50% in hard-to-treat cancers and a strong safety profile. The pipeline includes late-stage and bispecific assets, with multiple data readouts and partnership opportunities expected in the next two quarters.
-
MDNA11, an engineered IL-2 super agonist, is showing durable responses and favorable safety in advanced solid tumors, with key data to be presented at AACR. The pipeline includes a phase III-ready glioblastoma asset and innovative bifunctional Superkines, with strong financial runway.
-
MDNA-11, an engineered IL-2 super agonist, is showing promising safety and efficacy in phase 1-2 trials, with robust immune activation and durable responses in checkpoint inhibitor-refractory cancers. Multiple clinical readouts and expansion into new indications are expected in 2025.
Fiscal Year 2024
-
The AGM was conducted virtually, confirming quorum and following a set agenda. All board nominees were elected, and MNP LLP was reappointed as auditor. Voting results will be published, and a Q&A session was held for shareholder engagement.
-
The company is advancing a pipeline of engineered superkines, with MDNA11 showing promising efficacy and safety in early clinical trials, including responses in tumor types previously unresponsive to IL-2. Key data updates are expected in late 2024 and 2025, with a strong cash position supporting ongoing development.